×
Beyond Air EBITDA 2016-2025 | XAIR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Beyond Air ebitda from 2016 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Beyond Air EBITDA 2016-2025 | XAIR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Beyond Air ebitda from 2016 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$226.4B
Amgen (AMGN)
$166.3B
Gilead Sciences (GILD)
$141.3B
Vertex Pharmaceuticals (VRTX)
$122.5B
Bristol Myers Squibb (BMY)
$99.7B
CSL (CSLLY)
$85.2B
GSK (GSK)
$77.9B
Regeneron Pharmaceuticals (REGN)
$61.8B
Alnylam Pharmaceuticals (ALNY)
$42.5B
Argenex SE (ARGX)
$35.2B
BioNTech SE (BNTX)
$27.5B
Royalty Pharma (RPRX)
$20.2B
Insmed (INSM)
$19.6B
Biogen (BIIB)
$19.2B
Illumina (ILMN)
$16.6B
Genmab (GNMSF)
$14.9B
Genmab (GMAB)
$14.7B
Incyte (INCY)
$13.7B
Moderna (MRNA)
$13.4B
Exelixis (EXEL)
$12.4B
BioMarin Pharmaceutical (BMRN)
$11.4B
QIAGEN (QGEN)
$11.2B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Ascendis Pharma (ASND)
$10.4B
Exact Sciences (EXAS)
$9.1B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Bio-Techne Corp (TECH)
$8.7B
Blueprint Medicines (BPMC)
$8.3B
Legend Biotech (LEGN)
$8.1B
Roivant Sciences (ROIV)
$7.7B